Polymorphisms of ABCC5 and NOS3 genes influence doxorubicin cardiotoxicity in survivors of childhood acute lymphoblastic leukemia

[1]  M. Simmonds,et al.  Endothelial Nitric Oxide Synthase Single Nucleotide Polymorphism and Left Ventricular Function in Early Chronic Kidney Disease , 2015, PloS one.

[2]  D. Neuberg,et al.  Polymorphisms of Asparaginase Pathway and Asparaginase-Related Complications in Children with Acute Lymphoblastic Leukemia , 2014, Clinical Cancer Research.

[3]  Y. Pommier,et al.  Mitochondrial Topoisomerase I (Top1mt) Is a Novel Limiting Factor of Doxorubicin Cardiotoxicity , 2014, Clinical Cancer Research.

[4]  H. Hakonarson,et al.  Hyaluronan synthase 3 variant and anthracycline-related cardiomyopathy: a report from the children's oncology group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  Wei Zhang,et al.  Endothelial Nitric Oxide Synthase Gene G894T Polymorphism and Myocardial Infarction: A Meta-Analysis of 34 Studies Involving 21068 Subjects , 2014, PloS one.

[6]  S. Neuhausen,et al.  Genetic susceptibility to anthracycline‐related congestive heart failure in survivors of haematopoietic cell transplantation , 2013, British journal of haematology.

[7]  S. Lipsitz,et al.  Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemia , 2013, Cancer.

[8]  M. Hayden,et al.  Validation of variants in SLC28A3 and UGT1A6 as genetic markers predictive of anthracycline‐induced cardiotoxicity in children , 2013, Pediatric blood & cancer.

[9]  A. Tausche,et al.  Dexrazoxane Prevents the Development of the Impaired Cardiac Phenotype in Caveolin-1-disrupted Mice , 2013, Journal of cardiovascular pharmacology.

[10]  M. Krajinovic,et al.  Role of NOS3 DNA Variants in Externalizing Behavioral Problems Observed in Childhood Leukemia Survivors , 2013, Journal of pediatric hematology/oncology.

[11]  M. Relling,et al.  Postinduction dexamethasone and individualized dosing of Escherichia Coli L-asparaginase each improve outcome of children and adolescents with newly diagnosed acute lymphoblastic leukemia: results from a randomized study--Dana-Farber Cancer Institute ALL Consortium Protocol 00-01. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  M. Hayden,et al.  Pharmacogenomic prediction of anthracycline-induced cardiotoxicity in children. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Falus,et al.  ABCC1 polymorphisms in anthracycline‐induced cardiotoxicity in childhood acute lymphoblastic leukaemia , 2012, Cell biology international.

[14]  D. Neuberg,et al.  ATF5 polymorphisms influence ATF function and response to treatment in children with childhood acute lymphoblastic leukemia. , 2011, Blood.

[15]  C. Sotiriou,et al.  HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. , 2011, The Lancet. Oncology.

[16]  Tina Hernandez-Boussard,et al.  Doxorubicin pathways: pharmacodynamics and adverse effects , 2011, Pharmacogenetics and genomics.

[17]  M. Krajinovic,et al.  Polymorphism in multidrug resistance-associated protein gene 3 is associated with outcomes in childhood acute lymphoblastic leukemia , 2011, The Pharmacogenomics Journal.

[18]  S. Lipshultz,et al.  Anthracycline-Associated Cardiotoxicity in Survivors of Childhood Cancer , 2011, Pediatric Cardiology.

[19]  D. Neuberg,et al.  Long-term results of Dana-Farber Cancer Institute ALL Consortium protocols for children with newly diagnosed acute lymphoblastic leukemia (1985–2000) , 2009, Leukemia.

[20]  M. Krajinovic,et al.  Polymorphisms in multidrug resistance-associated protein gene 4 is associated with outcome in childhood acute lymphoblastic leukemia. , 2009, Blood.

[21]  G. Hasenfuss,et al.  Differential roles of nitric oxide synthase isozymes in cardiotoxicity and mortality following chronic doxorubicin treatment in mice , 2009, Naunyn-Schmiedeberg's Archives of Pharmacology.

[22]  S. Chong,et al.  Mining Potential Functionally Significant Polymorphisms at the ATP-Binding- Cassette Transporter Genes , 2009 .

[23]  I. Mlinarič-Raščan,et al.  Influence of the polymorphism in candidate genes on late cardiac damage in patients treated due to acute leukemia in childhood , 2009, Leukemia & lymphoma.

[24]  M. Relling,et al.  Genetic polymorphisms in the carbonyl reductase 3 gene CBR3 and the NAD(P)H:quinone oxidoreductase 1 gene NQO1 in patients who developed anthracycline‐related congestive heart failure after childhood cancer , 2008, Cancer.

[25]  M. Picard,et al.  Disruption of Nitric Oxide Synthase 3 Protects Against the Cardiac Injury, Dysfunction, and Mortality Induced by Doxorubicin , 2007, Circulation.

[26]  D. Neuberg,et al.  Results of the Dana-Farber Cancer Institute ALL Consortium Protocol 95-01 for children with acute lymphoblastic leukemia. , 2007, Blood.

[27]  M. Pfreundschuh,et al.  NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity , 2005, Circulation.

[28]  S. Lipsitz,et al.  Chronic progressive cardiac dysfunction years after doxorubicin therapy for childhood acute lymphoblastic leukemia. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[29]  S. Lipsitz,et al.  The effect of dexrazoxane on myocardial injury in doxorubicin-treated children with acute lymphoblastic leukemia. , 2004, The New England journal of medicine.

[30]  H. Caron,et al.  Anthracycline cardiotoxicity in children. , 2004, The New England journal of medicine.

[31]  S. Fogli,et al.  The role of nitric oxide in anthracycline toxicity and prospects for pharmacologic prevention of cardiac damage , 2004, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[32]  John D. Storey,et al.  Strong control, conservative point estimation and simultaneous conservative consistency of false discovery rates: a unified approach , 2004 .

[33]  U. Brinkmann,et al.  Expression and localization of the multidrug resistance protein 5 (MRP5/ABCC5), a cellular export pump for cyclic nucleotides, in human heart. , 2003, The American journal of pathology.

[34]  D. Labuda,et al.  Polymorphisms in genes encoding drugs and xenobiotic metabolizing enzymes, DNA repair enzymes, and response to treatment of childhood acute lymphoblastic leukemia. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  C. Trautwein,et al.  Gene Transfer of cGMP-Dependent Protein Kinase I Enhances the Antihypertrophic Effects of Nitric Oxide in Cardiomyocytes , 2002, Hypertension.

[36]  R. Zechner,et al.  Myocardial Contractile Function and Heart Rate in Mice With Myocyte-Specific Overexpression of Endothelial Nitric Oxide Synthase , 2001, Circulation.

[37]  M. Fukuoka,et al.  Induction of MRP5 and SMRP mRNA by adriamycin exposure and its overexpression in human lung cancer cells resistant to adriamycin , 2001, International journal of cancer.

[38]  D. Keppler,et al.  The Multidrug Resistance Protein 5 Functions as an ATP-dependent Export Pump for Cyclic Nucleotides* , 2000, The Journal of Biological Chemistry.

[39]  J. Huidobro-Toro,et al.  Molecular mechanism of cGMP‐mediated smooth muscle relaxation , 2000, Journal of cellular physiology.

[40]  J. Moss,et al.  Intracellular processing of endothelial nitric oxide synthase isoforms associated with differences in severity of cardiopulmonary diseases: cleavage of proteins with aspartate vs. glutamate at position 298. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[41]  J. Wojtacki,et al.  Anthracycline-induced cardiotoxicity: clinical course, risk factors, pathogenesis, detection and prevention--review of the literature. , 2000, Medical science monitor : international medical journal of experimental and clinical research.

[42]  M. Böhm,et al.  Acute effects of nitric oxide and cyclic GMP on human myocardial contractility. , 1997, The Journal of pharmacology and experimental therapeutics.

[43]  R. Olson,et al.  Time‐related increases in cardiac concentrations of doxorubicinol could interact with doxorubicin to depress myocardial contractile function , 1993, British journal of pharmacology.

[44]  N. Reichek,et al.  Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. , 1989, Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography.

[45]  R. Arceci Assessment of dexrazoxane as a cardioprotectant in doxorubicin-treated children with high-risk acute lymphoblastic leukaemia: long-term follow-up of a prospective, randomised, multicentre trial , 2011 .

[46]  W. N. Chen,et al.  Pharmacogenetics of target genes across doxorubicin disposition pathway: a review. , 2010, Current drug metabolism.

[47]  Duncan J. Stewart,et al.  The Role of NOS in Heart Failure: Lessons from Murine Genetic Models , 2004, Heart Failure Reviews.

[48]  M. Adamcová,et al.  Anthracycline-induced cardiotoxicity. , 2000, Acta medica.